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ABSTRACT 
This doctoral thesis investigated genetic, inflammatory, and lifestyle influences on cognition, 
brain structure, and dementia. The influence of TOMM40 polymorphisms (Study I), a 
PICALM, BIN1 and CLU genetic risk score (GRS; Studies II, III), and inflammatory 
cytokines (Study IV) was assessed, as well as potential interactions with physical activity 
(Studies II-IV). All studies were based on the Swedish National study on Aging and Care in 
Kungsholmen (SNAC-K), including a subsample that had participated in magnetic resonance 
imaging (MRI).  
In Study I, the influence of TOMM40 polymorphisms (rs11556505 and rs2075650) on 
episodic memory and hippocampal volume was investigated. There was no independent 
influence of TOMM40 polymorphisms on episodic memory and hippocampal volume. 
However, carriers of an APOE ε4 allele who also harbored TOMM40 risk alleles relied more 
heavily on hippocampal volume for episodic memory performance.  
Study II confirmed our hypothesis that high genetic risk (GRS >4) based on Alzheimer’s 
disease (AD) candidate genes (PICALM rs3851179, rs541458, BIN1 rs744373, and CLU 
rs11136000) was associated with worse episodic memory performance in non-demented 
older adults. Interestingly, there was an interaction between physical activity and GRS. The 
combination of physical inactivity and high genetic risk was most detrimental to memory 
performance, whereas a high GRS could be compensated for by physical activity. In Study 
III, we investigated if the same GRS was associated with incident dementia, primarily AD. 
Despite the associations with memory performance in Study II, there was no effect of GRS 
on incident dementia during a follow-up period of 6 years. Nonetheless, we did replicate 
previous work showing that physical inactivity is associated with increased risk of dementia.  
Study IV investigated the influence of inflammatory cytokines and physical activity on gray-
matter volume and global cognitive decline. Although there was no relation between 
inflammatory cytokines and brain volume, high levels of IL-12p40 in individuals who were 
physically inactive were associated with smaller lateral prefrontal cortex and hippocampal 
volumes, as well as with global cognitive decline over 6 years. This suggests that levels of 
inflammation may be especially detrimental for brain and cognitive integrity in individuals 
who are physically inactive.   
In summary, the studies in this thesis suggest that physical inactivity is associated with 
reduced episodic memory performance, compromised structural brain volume, and dementia 
risk. Moreover, physical inactivity in combination with a high GRS or systemic inflammation 
was especially detrimental to episodic memory as well as to frontal and hippocampal 
volumes, respectively. 
 
 
SAMMANFATTNING  
Den här avhandlingen undersökte betydelsen av gener, inflammation och livsstilsfaktorer för 
episodiskt minne, hjärnans struktur och risk för att utveckla demens. Rollen av TOMM40 
polymorfier (Studie I), PICALM, BIN1 och CLU genetisk riskpoäng (Studier II, III), och 
inflammatoriska markörer (Studie IV) belystes, samt om det fanns någon interaktion mellan 
dessa faktorer och fysisk aktivitet. Studierna baserades på data från SNAC-K och inkluderade 
en undergrupp som genomgått magnetisk resonanstomografi.  
I Studie I undersökte vi om TOMM40 polymorfier (rs11556505, rs2075650) var associerade 
med episodiskt minne och hippocampusvolym. Det fanns ingen association mellan TOMM40, 
episodiskt minne och hippocampus volym men de som var APOE ε4-bärare och dessutom 
bärare av en TOMM40 riskallel var mer beroende av hippocampus för episodiskt minne.  
Resultaten från Studie II bekräftade vår hypotes att en hög genetisk riskpoäng baserad på 
PICALM (rs3851179, rs541458), BIN1 (rs744373) och CLU (rs11136000) riskalleler var 
associerade med sämre episodiskt minne. Kombinationen av fysisk inaktivitet och hög 
genetisk risk var mest skadligt för episodiskt minne, medan en hög genetisk risk kunde 
kompenseras av fysisk aktivitet. Detta tyder på att individer med genetisk sårbarhet kan ha 
störst nytta av fysisk aktivitet. I Studie III undersökte vi om samma riskpoäng, baserad på 
riskgener för Alzheimers sjukdom var associerad med risk för demens, speciellt AD. Trots 
associationerna med episodiskt minne i Studie II fann vi ingen effekt av hög genetisk risk 
poäng på incidensen av nyinsjuknande i demens över 6 år. Dock replikerade vi tidigare 
studier genom att visa att fysisk inaktivitet är associerad med ökad risk för demens.   
Studie IV undersökte relationen mellan inflammatoriska cytokiner, fysisk aktivitet och 
hjärnvolym liksom kognitiv förmåga. Trots att det inte fanns en relation mellan 
inflammatoriska cytokiner på hjärnvolym var höga IL-12p40 värden hos fysiskt inaktiva 
individer associerade med mindre volym i lateral prefrontal cortex och hippocampus. Detta 
tyder på att höga värden av inflammation kan vara särskilt skadligt för hjärnvolym hos 
individer som är fysiskt inaktiva.  
Sammanfattningsvis visar studierna i denna avhandling att fysisk inaktivitet är kopplad till 
sämre minnesprestation, mindre hjärnvolym, och ökad risk för demens. Dessutom är fysisk 
inaktivitet i kombination med hög genetisk risk eller systemisk inflammation speciellt 
skadligt för episodiskt minne respektive frontal och hippocampusvolym.  
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1 INTRODUCTION  
“A fundamental characteristic of development across the lifespan – at multiple levels of 
analysis, and from birth to death – is that the human organism changes. It becomes different 
in form, nature, characteristics, and many other respects. The transformations that occur 
across the lifespan are changes that involve periods and varieties of gains, losses, and 
maintenance.” – Roger A. Dixon (2000) 
Inherent to this quote is the idea that change is not necessarily negative in nature. Already in 
1809, Darwin stated that “It is not the strongest of the species that survives, nor the most 
intelligent, but the one most responsive to change.” In terms of cognition, is it possible that 
some individuals are more resilient to changes and losses? Could some benefit more than 
others from environmental support? This thesis will discuss some of these fundamental 
questions concerning variability in cognitive performance in old age with a focus on genetic 
and lifestyle influences in aging and dementia.  
Although there is a mean negative age trend, not all cognitive domains decline in aging. In 
addition, there is a high degree of interindividual variability in old-age cognitive performance 
(Figure 1).  
 
 
Figure 1. Variability in cognitive performance at different ages. Reproduced with permission (Bäckman, 2008; 
Habib, Nyberg, & Nilsson, 2007). 
 
Nyberg and colleagues (2012) proposed the concept of brain-maintenance to encompass the 
variability seen in individual performance as we age. Offered as a complement to the concept 
of cognitive reserve, brain-maintenance focuses on aspects that preserve and maintain 
structural, chemical, and functional brain integrity as we age. Brain reserve implies a passive 
threshold suggesting that some individuals will withstand pathology, and maintain cognitive 
performance, depending on the individual’s initial brain resources. Only when this threshold 
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is passed will pathology influence performance negatively. Cognitive reserve is considered 
more active, and implies that an individual can maintain performance in old age by 
compensating for potential losses. Brain-maintenance focuses on factors that maintain brain 
integrity in old age. According to this view, variability in cognitive performance as we age 
may result from gene-environment interactions. This thesis aims to broaden our 
understanding of such interactions and their role in cognitive aging and dementia.  
In the following sections, I will discuss cognitive aging and its neural correlates. I will also 
give an overview of pathophysiological mechanisms in AD, which is relevant, given that the 
biomarkers examined are associated with this disease. This will be followed by a description 
of the genes, inflammatory markers, and environmental factors studied in this thesis.  
1.1 COGNITIVE AGING  
Aging is accompanied by changes in cognition that may or may not be associated with 
various disease states. However, even in disease-free conditions, some degree of cognitive 
decline is a natural part of the aging process. Understanding the cognitive changes that take 
place in normal aging is essential, not only to benefit the individuals influenced by these 
alterations, but also to investigate changes that ultimately lead to pathological aging such as 
dementia. Older adults show impairments in many cognitive domains, including executive 
functioning, working memory, processing speed, and episodic memory (Park & Schwarz, 
1999; Salthouse, 2000). Other areas remain relatively preserved in late life. In the next 
section I will focus on age-related changes in various memory domains, and the neural 
correlates of these changes.  
Memory can be divided into two major varieties: declarative memory (explicit) that entails 
conscious recollection of factual knowledge and events, and non-declarative (implicit) 
memory that involves memory without conscious awareness. Within the non-declarative 
domain, both priming and procedural memory show relatively little age-related decline 
(Bäckman, Small, Wahlin, & Larsson, 2000). Priming assesses performance changes of 
previously encountered stimuli, and procedural memory entails memory of events such as 
how to ride a bicycle. Within the declarative domain, semantic memory, which encompasses 
factual knowledge, also remains rather spared in aging (Rönnlund, Nyberg, Bäckman, & 
Nilsson, 2005). In contrast, episodic memory, although relatively stable until the age of 60, is 
the type of declarative memory that shows the largest degree of decline in aging (Rönnlund et 
al., 2005).  
Episodic memory is the type of memory domain that allows us to consciously recollect and 
re-experience past events that are unique to us as a person. This is the part of memory that 
holds the what, when and where of personal events, which allows us to form autobiographical 
memories keeping us rooted in time and space (Tulving, 1972). It has been described as a 
form of mental time travel (Tulving, 2002), and decrements in episodic memory performance 
is not only a cardinal feature of cognitive aging, but also one of the earliest signs of 
impending AD (Bäckman, Jones, Berger, Laukka, & Small, 2005; Jack et al., 2012). When 
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probing episodic memory performance, free recall is most impaired in old age, likely because 
it requires more cognitive resources at encoding and retrieval relative to recognition 
(Danckert & Craik, 2013). Recognition is less effortful and supported and therefore more 
preserved in aging. When probing recognition, one can further divide performance into 
recollection and familiarity in accordance with dual-process models of episodic memory 
(Yonelinas, 2001). In healthy aging, conscious recollection of an item is more negatively 
influenced, whereas the sense of familiarity of an item remains well preserved (Koen & 
Yonelinas, 2016). There has also been increased attention on associative memory, as research 
indicates that aging is associated with disproportionate deficits in binding pieces of 
information together in episodic memory (Naveh-Benjamin, 2000). In summary, several 
measures indicate that episodic memory is sensitive to the effects of aging, which is most 
likely due to its dependency on the medial temporal lobe (MTL) and the prefrontal cortex 
(PFC; Cabeza, Nyberg, & Park, 2016) that are particularly affected in old age (Raz et al., 
2005). 
Neuropsychiatric patients have made significant contributions to our understanding of the 
organization of memory systems, and the pivotal role that the MTL plays for memory. The 
work by Brenda Milner on the famous patient H. M. remains the most cited throughout the 
literature (Scoville & Milner, 1957; Squire, 2009). Suffering from epileptic seizures from 
young age, H. M’s MTL, including his hippocampus (HC), were resected bilaterally in an 
attempt to control his seizures. The treatment was successful in terms of mitigating the 
epileptic seizures, but resulted in severe memory impairments. H. M. presented with 
immediate memory deficits and was not able to remember individuals he had recently 
encountered: “Just before coming into the examining room he had been talking to Dr. Karl 
Pribram, yet he had no recollection of this at all and denied that anyone had spoken to him” 
(Scoville & Milner, 1957). Although his performance on the Wechsler-Bellevue Intelligence 
Scale was comparable to his preoperative state, H. M.´s performance on the Wechsler 
Memory Scale was far below average. Illustrative of his memory impairment, H. M. had no 
recollection of any previous attempts of the memory tasks (Scoville & Milner, 1957). Since 
then, neuropsychologists have studied H. M. and his case has continued to guide the field 
through the past decades, providing us with vast information about the organization of 
memory. 
Since H. M., the field of neuroimaging has developed, which has made it possible to assess 
neural correlates of memory in vivo among healthy persons. It has been established that the 
HC is important for episodic memory, yet the negative association between hippocampal 
volume and episodic performance has been controversial (Pohlack et al., 2014). Bigger may 
not always be better, and what is evident is that there is an increase in variability in old age 
(Van Petten, 2004). Nevertheless, there has also been support for a direct link between HC 
volume and memory (Head, Rodrigue, Kennedy, & Raz, 2008; Kalpouzos et al., 2009). There 
are substantial aging effects on the HC, with longitudinal studies showing 1.23% yearly HC 
decline in healthy older adults. This increases to an average of 1.7% annual decline after the 
7th decade of life (Raz & Rodrigue, 2006). This can be compared to the 3-4% annual decline 
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of the HC that can be seen in AD, and the substantially higher atrophy with up to 8% annual 
decline in individuals with genetic predisposition to AD (Fox et al., 1996).  
Next, we turn the discussion to biomarkers, mechanisms, and genetics relevant to brain aging, 
cognitive aging, and AD. Although only one study in the thesis (Study III) directly focuses on 
dementia, especially AD, the relatively lengthy treatment of pathology is motivated by the 
fact that the genes and biomarkers examined in non-demented aging for the most part 
originate from work on dementia, especially AD. 
1.2 ALZHEIMER’S DISEASE   
AD was first described by Alois Alzheimer, whose patient Auguste D presented with 
memory loss, sleep disturbances, and other psychological symptoms. Upon her passing, 
Alzheimer viewed the autopsy data and presented a talk about the case in Tübingen in 1906: 
“Her memory was most severely disturbed ...Slide preparations made with the Bielschovsky 
silver method show remarkable changes in the neurofibrils. In the interior of a cell that 
otherwise still appears normal, one or a few fibrils stand out through their thickness and 
impregnability.” – Alzheimer (1907). Later, Perusini (1909) advanced this work by 
emphasizing the neurofibrillary changes that were first described by Alzheimer. In 1910, the 
term Alzheimer’s Disease was coined in the Handbook of Psychiatry “Alzheimer described a 
peculiar group of cases with very severe cellular changes. . . the clinical interpretation of 
Alzheimer’s disease is still unclear” – Kraepelin (1910)   
Thus, already in 1906 one of the main pathological hallmarks of AD was described, even 
though little was understood about the clinical interpretation of the disease. Today we know 
more about the clinical presentation but there is still much to discern regarding the 
pathophysiological changes that ultimately cause the disease. Some prescribe to the amyloid 
hypothesis, others put emphasis on neurofibrillary tangles, and still others argue that 
mitochondria and inflammatory processes are key causative factors of AD. Although there 
has been progress in the field, after decades of research we still have much to learn about the 
etiology.    
AD is the leading cause of dementia, accounting for 50-70% of cases, and is characterized by 
progressive decline in cognition, primarily within the domains of episodic memory, 
perceptual speed and executive functioning (Bäckman et al., 2005). The onset is insidious and 
patients can present as primarily amnestic with deficits in recall of recently acquired 
information, or have deficits in one additional cognitive domain. Early signs of the disease 
include, but are not limited to, trouble recalling recent events, mood swings, confusion, 
disorientation, behavioral changes, and difficulties with activities of daily living (ADL; 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 
4th ed., 1994). With age being a primary risk factor for AD, the increasing aging population 
suggests that the number of individuals with dementia will increase (for a review, see 
Winblad et al., 2016), and approximately 66 million people are estimated to have dementia 
by 2030 (Prince et al., 2013). This in turn is associated with great societal challenges and the 
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worldwide cost of dementia in 2010 was estimated to be 604 billion US$ (Wimo, Jönsson, 
Bond, Prince, & Winblad, 2013). This makes the race to find a cure, and to identify groups 
who may benefit from targeted interventions, increasingly important. Genetic and lifestyle 
factors may be key in identifying individuals at risk that could benefit from targeted 
interventions. But first an overview of the primary mechanisms thought to lead to AD. 
1.2.1 The role of amyloid in Alzheimer’s disease    
It is widely accepted that AD is characterized by pathological changes in the brain that 
commence years before any clinical symptoms are present. Since the amyloid-cascade 
hypothesis was formulated (Hardy & Allsop, 1991), where amyloid deposition was proposed 
as the primary event in AD, researches have focused on the role of amyloid in AD. However, 
both amyloid plaques and neurofibrillary tangles are part of the histopathological signature of 
AD, and although amyloid has been considered a trigger in AD, abnormal phosphorylation of 
tau and the formation of neurofibrillary tangles has been described to be the bullet (Bloom et 
al., 2014). Genetic and postmortem findings support the amyloid hypothesis, yet many 
amyloid-based therapeutic approaches have failed to show efficacy (Karran & De Strooper, 
2016). Moreover, there are some testable predictions of the theory that have not been 
validated scientifically. For example, individuals can have clinical symptoms of dementia in 
the absence of amyloid pathology, or vice versa, suggesting that the presence of amyloid in 
the brain is not sufficient to cause the disease. Findings that up to 47% of cognitively intact 
individuals have amyloid-positive brain scans, suggests that amyloid deposition may be a part 
of normal aging (Chételat et al., 2013).  
There is a possibility that clinical trials have failed to show efficacy of amyloid-based 
therapies, because they target individuals too late in their disease progression (Morris, Clark, 
& Vissel, 2014). An increasing body of evidence shows that amyloid beta (Aβ) and tau 
interact, and perhaps such mechanisms or other interactions have not been given enough 
consideration (Bloom et al., 2014). Findings of amyloid in cognitively intact individuals 
(Chételat et al., 2013) does not negate that amyloid plays an important role in AD. 
Nonetheless, it is likely that other mechanisms are also involved and influence the onset of 
AD. 
“And while there is fear in the field over the consequences of rejecting it outright, clinging to 
an inaccurate disease model is the option we should fear most” – Herrup (2015) 
1.2.2 Mitochondria  
The mitochondrial cascade hypothesis has been proposed as an alternative to the amyloid-
cascade hypothesis, and suggests that age-related mitochondrial dysfunction is an important 
source of the AD pathogenesis. There is genetic and neuropathological research supporting 
the role of mitochondria and oxidative stress in AD (Devi, Prabhu, Galati, Avadhani, & 
Anandatheerthavarada, 2006; Hedskog, Zhang, & Ankarcrona, 2012; Lin & Beal, 2006; 
Reddy & Beal, 2005; Roses et al., 2010). Post-mortem morphological changes of the 
mitochondria among AD patients have been found in HC, neocortex, and locus coeruleus 
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(Baloyannis, 2006; Hirai et al., 2001). Interestingly, these changes did not co-occur with 
amyloid deposition, suggesting that morphological changes within the mitochondria may be 
an early and primary pathogenic event in AD (Baloyannis, 2006). The mitochondrial import 
channels may be especially important in this aspect, as amyloid beta precursor protein (APP) 
has been found lodged in these channels in AD patients. Such mitochondrial APP appears to 
be especially prevalent in individuals with genetic susceptibility to AD (Devi et al., 2006). 
The role of mitochondria and oxidative stress has been implicated in many neurodegenerative 
diseases. However, more research is needed to understand their roles in normal as well as 
pathological aging. In Study I, we investigate the role of translocase of outer mitochondrial 
membrane 40 (TOMM40) on HC volume and episodic memory performance in normal aging.  
1.2.3 Inflammation  
Another possible mechanism in AD is inflammation; its presence has been observed in the 
brain of individuals who subsequently develop AD as early as 20 years prior to diagnosis 
(Rodriguez-Vieitez et al., 2016). Moreover, inflammatory cytokines, such as c-reactive 
protein (CRP), and  interleukin-6 (IL-6), appear to be upregulated in AD and can be used as 
blood plasma biomarkers (Schneider, Hampel, & Buerger, 2009). As we age, the immune 
system becomes increasingly dysfunctional, such that the efficiency in clearing pathogens 
decreases and senescent cells increase their secretion of pro-inflammatory cytokines (López-
Otín, Blasco, Partridge, Serrano, & Kroemer, 2013).  
The few studies that are available suggest that inflammation is associated not only with the 
risk of dementia, but may contribute to variability in cognitive and brain aging (Marsland et 
al., 2015). For instance, high levels of IL-6 has been associated with decrements in cognitive 
performance (Lim, Krajina, & Marsland, 2013), smaller overall gray-matter volume 
(Marsland et al., 2015), and HC volume in midlife (Marsland, Gianaros, Abramowitch, 
Manuck, & Hariri, 2008). These findings suggest that peripheral markers of inflammation are 
associated with brain integrity and that low-grade systemic inflammation can precede 
cognitive decline (Marsland et al., 2008). 
Chronic peripheral inflammation activates microglia in the brain, and may influence memory 
and cognition negatively by disrupting neurogenesis in HC (Chesnokova, Pechnick, & 
Wawrowsky, 2016). Cytokines, including interleukin-1β (IL-1β), IL-6 and tumor necrosis 
factor-alpha (TNF-α), have an influence on synaptic plasticity, neurogenesis, and 
neuromodulation and, as such, play an important role in the cellular mechanisms involved in 
learning and memory (McAfoose & Baune, 2009). Granulocyte-colony stimulating factor (G-
CSF) is a cytokine that modulates the immune response by inhibiting pro-inflammatory 
cytokines. It has been shown that high levels of G-CSF are associated with decreased 
amyloid-deposition in HC, and decreased activity of pro-inflammatory cytokines in plasma 
(Sanchez-Ramos et al., 2009). Moreover, decreased levels of G-CSF have been observed in 
AD patients, suggestive of a disturbed immune response (Laske, Stellos, Stransky, Leyhe, & 
Gawaz, 2009). IL-12p40 may also influence inflammatory processes in the brain, with high 
levels of IL-12p40 being detrimental to brain aging. Knock-out models of the IL-12p40 
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receptor complex in mice is associated with decreased amyloid load, reduced neuronal and 
synaptic loss and reversed cognitive impairment (Tan et al., 2014). Moreover, inhibiting IL-
12 signaling pathways is associated with reduction in AD-like pathology and cognitive 
decline in animal models (vom Berg et al., 2012).  
There is limited research on the influence of inflammatory cytokines in healthy aging. The 
extent to which systemic inflammation influences brain and cognitive aging remains to be 
elucidated. Study IV of the current thesis examined the role of systemic inflammation in 
cognitive aging as previous research, albeit limited, indicates that inflammation plays a 
pivotal role in influencing brain areas known to decline in aging. 
1.3 ALZHEIMER´S DISEASE CANDIDATE GENES 
Phenotypes such as AD, episodic memory and HC volume are considered to be complex 
traits, as they are influenced by both genetic and environmental factors. By observing the 
concordance rate in monozygotic twins, the heritability of AD has been estimated to be up 
to 58% (Gatz et al., 2006; Pedersen, Gatz, Berg, & Johansson, 2004). For memory and HC 
volume, the estimated heritability is up to 65% (Blokland, de Zubicaray, McMahon, & 
Wright, 2012; Mather et al., 2015). These numbers indicate that, although heritability is 
high, these phenotypes are also under environmental influence. There are several methods 
for investigating the genetic influence on various phenotypes. Linkage studies examine 
chromosomal regions and how they segregate within families for certain diseases. Genetic 
association studies can involve candidate-gene approaches or genome wide association 
studies (GWAS) to scan for variation in single nucleotide polymorphisms (SNPs) that 
contribute to a particular phenotype. SNPs represent variation at a specific nucleotide in our 
DNA, and these are the variations that make up our individual features. GWAS allows us to 
compare the association between millions of SNPs and phenotypes by comparing disease 
status (case-control) or by using quantitive traits (i.e. HC volume). This can then be followed 
up by candidate-gene studies when there is sufficient knowledge about the association of 
certain SNPs and the phenotype of interest (Goldberg & Weinberger, 2009), which was the 
method used in this thesis.  
The early-onset form of AD (EOAD) runs in families and mutations within three major 
genetic loci have been associated with EOAD; APP, PSEN1, and PSEN2 (see 
http://www.molgen.vib-ua.be/ADMutations). However, EOAD only accounts for about 1% 
of the AD cases, and the sporadic late-onset form, referred to as AD throughout this thesis, 
is the  most common form of the disease (Bekris, Yu, Bird, & Tsuang, 2010). GWAS have 
identified several genetic risk factors for AD (for a review, see Ferencz & Gerritsen, 2015). 
In the current work, we examine some of the top candidate genes that have been previously 
associated with AD. Besides being primary candidate genes of AD, the targeted SNPs may 
also influence cognitive performance, especially episodic memory, in healthy aging (Barral 
et al., 2012; Nilsson et al., 2006), although the evidence is sparse. In the following section I 
will give an overview of the primary candidate genes and their phenotypic associations.  
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1.3.1 APOE  
There are genetic variations in the population that are common and have a large influence 
on disease burden, although they do not act in a deterministic fashion. The impact of such 
loci is deemed high (OR ≥2) or low (OR <2) depending on their association with AD 
(Winblad et al., 2016). One locus, which has been consistently associated with dementia is 
APOE. APOE is located on chromosome 19q13 and comes in three allelic variants, ε2, ε3, 
and ε4 which have a worldwide frequency of 8.4%, 77.9% and 13.7% respectively (Liu, 
Kanekiyo, Xu, & Bu, 2013). The ε4 allele has been associated with up to 4 times higher 
risk of AD (Bertram, McQueen, Mullin, Blacker, & Tanzi, 2007), accounting for more than 
half of the genetic variance in the disease (Ridge et al., 2013). Discovered already in 1991 
(Pericak-Vance et al., 1991), it remains one of the major genetic risk factors of AD.  
The ε4 allele is also associated with reduced memory and perceptual speed performance 
(Laukka et al., 2013; Nilsson et al., 2006) and, gray- and white-matter integrity in healthy 
aging (for a review, see Ferencz, Karlsson, & Kalpouzos, 2012). The less common ε2 allele 
appears to have a protective effect in AD, and may influence longevity (Raichlen & 
Alexander, 2014). APOE is involved in the transport of lipids in the central nervous system 
(CNS), yet the mechanisms by which the lipoprotein influences the brain remain largely 
unknown. Having an ε4 allele may influence the delivery of cholesterol to the neurons 
resulting in disturbed lipid homeostasis in the brain (Poirier, 2006), and APOE interacts with 
amyloid affecting aggregation as well as clearance (Holtzman, 2004). However, already in 
their early discovery of APOE, Roses and colleagues (2006) argued that neither APOE nor 
amyloid is the central cause of AD. They highlighted the role of APOE in glucose 
metabolism, and the fact that it binds tighter to amyloid. Amyloid and tau aggregation was 
suggested to be a downstream event resulting from years of decreased glucose metabolism. 
Despite the strong association, APOE does not explain all of the genetic variation in AD, 
which suggests that other common variants may play a role in the disease. One such gene, 
TOMM40, has highlighted the important role that mitochondria may play in AD. 
1.3.2 TOMM40  
TOMM40, located on chromosome 19q13 codes the channel forming subunit of the outer 
mitochondrial membrane that influences the import of protein precursors to the mitochondria 
(Humphries et al., 2005; Maglott, Ostell, Pruitt, & Tatusova, 2005). Striking at first glance is 
the close approximation to APOE, also located on 19q13. Due to their linkage disequilibrium 
(LD) on chromosome 19, TOMM40 and APOE have mostly be considered in unison. A closer 
look at the phylogenetic structure in this region shows that APOE ε4 is linked to a long poly-
T variant of TOMM40 (rs10524523), whereas APOE ε3 is linked to either a short or very 
long T variant. The initial studies by Roses and colleagues (2010) used a phylogenetic 
approach where they found that a long poly-T variant (rs10524523) was associated with 
higher risk for late onset AD. When assessing individuals with APOE ε3/ε4 who developed 
AD after the age of 60 they found that those who carried an APOE ε3 allele in combination 
with long poly-T length developed AD on average 7 years earlier in comparison to those 
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who had an APOE ε3 allele with short poly-T repeat. Furthermore, this combination was 
associated with increased tangle formation (Li et al., 2013). However, these findings have 
not always been replicated (Cruchaga et al., 2011), and the feasibility of this approach has 
been questioned (Guerreiro & Hardy, 2012). Nonetheless, a recent AD genetic risk 
algorithm was developed, based on APOE, TOMM40 poly-T length, and age (Lutz, 
Sundseth, et al., 2016). This combination had higher predicative value than APOE alone 
(Lutz, Sundseth, et al., 2016). Whether or not there is a true independent effect of 
TOMM40, it seems like there is an increased utility of combining TOMM40 with APOE and 
other risk factors of AD. This suggests that we should consider these genes in unison rather 
than as independent factors (Lutz, Sundseth, et al., 2016; Lutz, Crenshaw, Welsh-Bohmer, 
Burns, & Roses, 2016).  
In the current thesis, we focus on other TOMM40 polymorphisms. As with the phylogenetic 
approach, findings concerning TOMM40 polymorphisms have been conflicting due to its 
linkage with APOE. Nonetheless, focusing on the haplotype structure of this region may be 
a better approach; it was demonstrated that a haplotype of rs2075650, rs11556505 
(TOMM40) and rs429358 (APOE) was associated with AD (Potkin et al., 2009). We know 
that imaging and cognitive markers, such as hippocampal atrophy and episodic memory, 
are important predictors of AD (Bäckman, 2008; Jack et al., 2012). However, the extent to 
which variations in TOMM40 influence hippocampal structure and episodic memory 
remains less well known. One approach to assess the influence of TOMM40 on 
hippocampal volume has been to use hippocampal volume as a quantitative trait in GWAS. 
This approach has indicated that TOMM40 rs2075650 is associated with hippocampal 
volume (Shen et al., 2014). Recently, studies from the Lothian birth cohort have found that 
TOMM40 poly-T length was also associated with white-matter integrity (Lyall et al., 
2014a), but not cognitive aging (Lyall et al., 2014b). Others have shown an association with 
episodic memory (Pomara et al., 2011; Yan et al., 2015). However, less is known about the 
APOE-independent influence of TOMM40 rs11556505 and rs2075650 SNPs on episodic 
memory and HC volume in old age, which we address in Study I.   
1.3.3 PICALM, BIN1, and CLU  
GWAS, with up to 17 000 cases and over 30 000 controls, have identified several AD 
candidate genes (Figure 2; Harold et al., 2009; Lambert, 2013), with PICALM, BIN1 and 
CLU being among the top candidate genes (Bertram et al., 2007). PICALM, located on 
11q14.2, encodes the clathrin-assembly protein (Maglott et al., 2005). The PICALM rs541458 
C allele and rs3851179 A allele are associated with decreased risk of AD (Bertram et al., 
2007). PICALM has been primarily found in endothelial cells, the lining of the blood vessels, 
and is also present in neurons, astrocytes, and oligodendrocytes. PICALM influences clathrin-
mediated endocytosis, a process by which ligands, proteins, lipids, growth factors, and 
neurotransmitters are transported from the extracellular matrix into the cytoplasmic 
environment. PICALM has been suggested to play a role in AD by influencing both amyloid-
dependent and independent pathways. The amyloid-independent pathways suggest that  
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Figure 2. Manhattan plot for genome wide association with AD (Lambert, 2013) indicating PICALM, BIN1 and 
CLU as top candidate genes for the disease.  
 
PICALM may influence lipid metabolism, immune disorders, and iron homeostasis (Xu, Tan, 
& Yu, 2014). Another potentially interesting pathway by which PICALM may exert a 
negative influence is by allowing the transport of Aß through the blood-brain barrier (BBB, 
Zhao et al., 2015). PICALM also influences hippocampal degeneration (Melville et al., 2012), 
and entorhinal thickness (Furney et al., 2011), key areas implicated in cognitive aging and 
AD. Some initial studies suggested that PICALM may modulate the effects of APOE, with 
regard to prefrontal volumes and performance on tests of processing speed and working 
memory (Morgen et al., 2014). Yet, little is known about the APOE-independent contribution 
of PICALM to episodic memory, and potential interactions with other top AD candidate 
genes.  
BIN1, located on chromosome 2q14.3, is also expressed in the CNS. It is thought to influence 
synaptic-vesicle endocytosis, interact with clathrin, and influence apoptotic processes 
(Maglott et al., 2005). BIN1 influences similar pathogenic mechanisms as PICALM, including 
lipid metabolism, clearance of amyloid across the BBB, and neurofibrillary tangle formation 
(Jones, Harold, & Williams, 2010; Zlokovic et al., 1996). After APOE, BIN1 rs744373 is one 
of the most replicated AD genetic risk polymorphisms, with up to 1.17 higher risk of AD in 
G allele carriers (Bertram et al., 2007). Despite these findings, little is known about the 
pathogenic influence of BIN1 in AD. It has been demonstrated that BIN1 protein expression 
is elevated in AD brains, especially in HC, and that the elevation coexists with tangle 
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formation, but not amyloid deposition, suggesting that BIN1 may also influence amyloid-
independent pathways (Holler et al., 2014). Moreover BIN1 polymorphisms have been 
associated with several AD biomarkers including atrophy of the HC, elevated tau in CSF, 
glucose metabolism, but not amyloid deposition (Wang et al., 2016).Yet, little is known of 
the influence of BIN1 on episodic memory. Some recent findings implicate BIN1 loci in 
working memory performance in healthy young adults (Zhang et al., 2015), and episodic 
memory performance in type-2 diabetes (Greenbaum et al., 2016).  
Finally, the CLU gene, located on 8p21.1, codes for the protein clusterin. Described as a 
“forgotten player” in AD, research showed already 20 years ago that there is an increase in 
the expression of clusterin in AD (May et al.,1990; Nuutinen, Suuronen, Kauppinen, & 
Salminen, 2009). The gene product clusterin may have a negative influence on AD 
pathogenesis. It has been implicated in amyloid-dependent pathways including, clearance, 
and transport of amyloid across the BBB. Together with APOE, clusterin is considered a 
major chaperone when it comes to clearing the brain of amyloid. However, it has also been 
suggested that clusterin is protective and involved in anti-apoptotic processes enhancing cell 
survival, and the question has been posed if clusterin is a “guardian or enemy” in AD 
(Nuutinen et al., 2009). It remains to be seen how CLU influences episodic memory. So far 
only one study has found an association between CLU and episodic memory performance, 
and then only in combination with PICALM (Barral et al., 2012).  
APOE remains the strongest genetic marker for AD, and although PICALM, BIN1 and CLU 
are associated with AD, their impact remains small in comparison. This suggests that we 
may benefit from considering the combined effects of these polymorphisms on episodic 
memory and AD. Considering that these SNPs are involved in similar pathogenic 
mechanisms also speaks in favor for analyzing them in unison. In fact, researchers have 
started to utilize this type of GRS or multi-locus approach when analyzing the genetic 
contribution to pathological (Escott-Price et al., 2015; Rodríguez-Rodríguez et al., 2013), 
and healthy (Barral et al., 2012) aging; however there is limited research on how these 
specific SNPs influence episodic memory.  
Besides the studies in this thesis, and a replication thereof (Papenberg, Becker, et al., 2016), 
only one other study has associated genotype patterns of CLU and PICALM with episodic 
memory performance in normal aging. Here, the combination of the CLU rs11136000 T 
allele together with the PICALM rs3851179 G allele was most detrimental to episodic 
memory performance (Barral et al., 2012). Others have found that this same combination is 
associated with reduced hippocampal volume in healthy aging (Yang, Li, Liu, Li, & Jiang, 
2016). Yet, the same CLU allele may also be protective together with the PICALM protective 
A allele (rs3851179), which suggests that more research is needed before we can fully 
understand the combined effects of these SNPs in normal cognitive aging and dementia. 
Other studies have also indicated that these SNPs may influence hippocampal volume in a 
polygenic way (Chauhan et al., 2015; Harrison et al., 2016), which suggests that they may 
be especially important for episodic memory in aging. However, it remains to be seen 
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whether a combined risk score based on these genes influences episodic memory and risk 
of AD, and if this association is independent of APOE. Finally, it is of interest to examine 
whether these associations may be influenced by environmental factors, such as remaining 
active in old age. In the next section, I will discuss the benefits of physical activity in 
cognitive and brain aging.  
1.4 PHYSICAL ACTIVITY  
Physical inactivity is an important modifiable risk factor of AD (Winblad et al., 2016), and it 
has been shown that a physically active lifestyle can reduce the risk of dementia and AD with 
up to 45% (Hamer et al., 2009). Although the aging population is increasing there are 
indications that the incidence of dementia in Western Europe may be decreasing (Qiu, Von 
Strauss, Bäckman, Winblad, & Fratiglioni, 2013; Wu et al., 2016). This does not mean that 
we do not face a big societal challenge; the aging population is increasing and the number of 
individuals affected by dementia and AD is estimated to continue to rise (Winblad et al., 
2016). Reducing risk factors for AD (e.g., physical inactivity) with only 10% may prevent up 
to 1.1 million cases annually. While the ultimate goal is to find a cure for dementia and AD, 
primary prevention strategies with a life-course perspective may prove to be more fruitful in 
the foreseeable future (Winblad et al., 2016). Genes are not considered modifiable risk factors 
of AD, yet they may be more plastic than we initially believed (Belsky et al., 2009). As such, 
we may benefit from investigating gene-environment interactions in AD, and elucidate the 
influence of physical activity on genetic risk of dementia and AD.     
We have known for centuries that physical activity is beneficial for our health. “Lack of 
activity destroys the good condition of every human being, while movement and methodical 
physical exercise save and preserve it.” – Plato 350 BC. According to world health 
organization (WHO) recommendations, older adults should participate in health and/or 
fitness enhancing physical activity about 30 minutes daily (Nelson et al., 2007; WHO, 2010). 
Both health-enhancing (usual paced walks, short bike rides), and fitness-enhancing (brisk 
walks, jogging) are beneficial for health, but only the latter may influence physical fitness 
(Rydwik et al., 2013). In this thesis, we use self-reported measures of physical activity, 
including activities that are both aerobic and non-aerobic in nature. These measures of 
physical activity are different from physical exercise and exercise interventions, where 
studies focus on enhancing aerobic capacity in response to an intervention (for a review, see 
Erickson, Leckie, & Weinstein, 2014). Nonetheless, both measures of physical activity and 
exercise are associated with health benefits in aging.  
An increasing amount of work suggests that physical activity is beneficial for cognitive and 
brain aging, and indicates that an active lifestyle can prevent neurodegeneration (Erickson et 
al., 2014; Kramer & Erickson, 2007; Voelcker-Rehage & Windisch, 2013). Still some 
randomized trials only show modest benefits of physical activity on cognition 
(Lautenschlager, Cox, & Cyarto, 2012). According to the brain-maintenance view, physical 
activity supports the aging brain and variability in cognitive performance in old age may be 
due to differences in genetic and lifestyle factors such as physical activity. In line with this 
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notion, a physically active lifestyle is positively associated with episodic memory (Klaming, 
Annese, Veltman, & Comijs, 2016). Further support that physical activity may be especially 
important for memory comes from imaging studies. These have consistently shown that 
physical activity and aerobic exercise is associated with increased gray-matter volume, 
primarily in PFC and HC (Erickson et al., 2009; Kramer & Erickson, 2007). Aerobic exercise 
in old age was shown to increase the volume of the HC with 2%, which indicates that it has 
the potential to reverse age-related loss in hippocampal volume with up to 2 years (Erickson 
et al., 2009).  
Exercise may serve to protect against neurodegeneration by reducing oxidative stress 
(Marosi et al., 2012), inducing neurogenesis (Kempermann, 2008), and modulating 
angiogenesis (Lista & Sorrentino, 2010). Moreover, physical activity may buffer against 
neurodegeneration by modulating the effects of inflammation. Indeed, Hamer and 
colleagues (Hamer et al., 2012) demonstrated that regular engagement in physical activity 
lowers markers of systemic inflammation in blood, suggesting that physical activity may be 
beneficial in counteracting a negative inflammatory state often observed in aging and 
dementia. It remains to be seen whether physical activity interacts with inflammation to 
influence brain structures in aging. 
1.4.1 Gene-lifestyle interactions  
As we age and brain resources dwindle, genetic effects on the brain and subsequently 
cognition become more apparent (Papenberg, Lindenberger, & Bäckman, 2015). Physical 
activity may be especially beneficial for at-risk individuals in terms of protecting them 
against cognitive decline. As such, genetic influence on memory in late life, may be 
counteracted by a physically active lifestyle (Nyberg et al., 2012). 
We do not traditionally consider genes as plastic. Yet, the differential susceptibility model 
posits that genes may be just that. Rather than simply conferring risk to neurodegeneration, 
individuals who harbor risk genes may be more prone to benefit from positive 
environmental influences, such as being physically active (Belsky et al., 2009). For 
example, carriers of APOE ε4 alleles who are physically active have less hippocampal 
atrophy than their sedentary counterparts (Smith et al., 2014). Similar findings have been 
seen in epidemiological studies, where physical activity modifies the risk of AD among 
carriers of the APOE ε4 allele, suggesting that they may benefit the most from lifestyle 
interventions (Kivipelto et al., 2008; Rovio et al., 2005). However, not all have been able to 
confirm this association and it has also been suggested that physical activity may be more 
beneficial for non-ε4 carriers (Podewils et al., 2005). It remains to be seen how physical 
activity interacts with other genetic risk loci such as PICALM, BIN1 and CLU, in terms of 
their influence on cognitive aging and dementia. Although it has been shown that these 
genes are associated with episodic memory performance, it is not known if the effects of 
PICALM, BIN1 and CLU are modified by physical activity.   
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1.5 SUMMARY AND STUDY OBJECTIVES 
An increasing body of research suggests that variability in cognitive performance as we age is 
a result of complex gene-environment interactions. Yet, there is limited research on some of 
the most recently discovered candidate genes in terms of episodic memory performance and 
AD risk in old age, and whether some of these effects are mitigated by physical activity. 
Moreover, there has not been enough focus in the literature on APOE-independent influences 
of these genes. Whether considered independently or in unison with APOE, the influence of 
other genetic polymorphisms, such as PICALM, and TOMM40, is important, as they may 
provide insight into mechanisms relevant to episodic memory and neurodegeneration in 
aging. Understanding genetic and inflammatory contributions to memory, brain aging, and 
AD could provide an indication of key mechanisms that ultimately lead to neurodegeneration 
and AD. Moreover, physical activity remains one of the most important modifiable risk 
factors for AD, yet its interactions with genetic polymorphisms and inflammatory markers 
remain largely unexplored.  
The current thesis aims to investigate the effects of genetic and inflammatory biomarkers to 
understand complex phenotypes such as episodic memory, brain aging, and dementia. To 
understand these phenotypes, we examine AD candidate genes and inflammatory cytokines 
that have shown promising associations in the literature. Moreover, we aim to assess if there 
are interactions with physical activity, addressing whether individuals who are most 
susceptible to neural decline benefit the most from physical activity.  
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2 AIMS 
The general aim of this thesis is to investigate the effects of genetic and inflammatory 
biomarkers on episodic memory, brain structure and dementia in old age. Moreover, do 
lifestyle factors such as remaining active in old age interact with any of these factors? The 
specific aims of each study in this thesis are: 
Study I: To estimate the influence of TOMM40 variants on episodic memory and 
hippocampal volume in old age. 
Study II: To investigate if an aggregate GRS of PICALM, BIN1 and CLU variants is 
associated with episodic memory and if being physically active modifies this association. 
Study III: To investigate if an aggregate GRS of PICALM, BIN1 and CLU variants is 
associated with incident dementia and if being physically active modifies this association. 
Study IV: To examine the influence of physical activity and inflammatory biomarkers on 
brain structure and cognitive decline in aging.  
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3 METHODS  
3.1 THE SNAC-K PROJECT  
All the studies in the current thesis are based on the population-based SNAC-K project. Data 
collection for SNAC-K commenced in 2001, with the primary aim to improve health and care 
for the elderly population and to identify factors associated with healthy aging and dementia. 
For this purpose, 5111 individuals (≥60 years) from the Kungsholmen municipality of 
Stockholm, Sweden, were invited to participate. Of these, 4590 were alive and eligible, and 
3353 (73%) participated in the baseline assessment that entailed a nurse interview, a medical 
examination, and a neuropsychological testing session. In total, these examinations lasted 
approximately 6 hours. The number of individuals who completed the cognitive test battery at 
baseline was 2848. In addition, a subsample of 555 participants that were eligible for 
scanning underwent MRI assessment. 
The sample was stratified on age (60, 66, 72, 78, 81, 84, 87, 90, 93, 96, and 99+ years). First 
follow-up for the older cohorts (age 78+ years at baseline) was conducted during 2004-2006 
(3-year follow-up); second follow-up for the older cohorts and first follow up for the younger 
cohorts (age 60-72 years) was performed 2007-2010.  
Study I and IV analyzed data from the baseline sample that underwent MRI. Study II used 
data from the baseline cognitive assessment and in Study III variables collected at baseline 
were used to predict new cases of dementia at 3 and 6-year follow-up. In all studies, 
individuals with a dementia diagnosis or other neurological disorders, such as Parkinson’s 
disease, at baseline were excluded.   
3.2 COGNITIVE ASSESMENT  
The cognitive assessment in SNAC-K lasted approximately 1.5 hours and was administered 
by trained psychologists in accordance with standardized procedures. In order to minimize 
practice effects and the effects of fatigue on a particular task, three different versions of the 
test battery were prepared and administered in two different orders.  
Episodic memory was measured using tests of free recall and recognition. Sixteen unrelated 
nouns were presented to participants visually and verbally. Total number of words recalled 
during a 2-minute period was used as a measure of free recall. Recognition was assessed 
using a self-paced yes-no recognition task where participants were presented with 32 nouns 
(16 old, 16 new). When identifying a word as “old”, participants were asked to report if they 
(a) clearly remembered hearing and/or seeing the presented word in the previous list 
(recollection), (b) recognized the word, but had no recollection of it (familiarity), or (c) could 
not determine remembering or recognizing the word (guessing). Recognition and recollection 
were assessed in terms of discrimination (hits-false alarms). 
Semantic memory was measured using vocabulary and general knowledge tests. In the 
vocabulary task, participants were presented with 30 words and instructed to identify the 
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corresponding synonyms among 5 alternatives within a time limit of 7 minutes (Dureman, 
1960; Nilsson, et al., 1997). The general knowledge task was comprised of 10 questions (e.g., 
“What is the capital of Uruguay?”), and participants were instructed to choose between two 
response alternatives (Dahl, Allwood, & Hagberg, 2009). For both tasks, number of correct 
responses was used as the outcome measure.  
Perceptual speed was assessed with the digit cancellation (Zazzo, 1974) and pattern 
comparison (Salthouse & Babcock, 1991) tasks. For digit cancellation, participants were 
instructed to cross out the digit “4” from rows of intermixed digits during 30 s. In pattern 
comparison, participants were asked to judge whether pairs of line segments were the “same” 
or “different” during 30 s. Number of crossed out “4s” and average correct pattern 
comparisons from two trials were used as outcome measures.  
Verbal fluency was assessed by letter and category fluency tasks (Lezak, Howieson, Loring, 
Hannay, & Fischer, 2004). Participants were asked to generate as many words as possible 
starting with the letters F and A for letter fluency, and from the categories of animals and 
professions for category fluency. They were allotted 60 s for each task and the average 
number of generated words was analyzed.   
3.3 DEMENTIA DIAGNOSIS  
Dementia diagnosis in SNAC-K was based on Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition criteria (American Psychiatric Association: Diagnostic and Statistical 
Manual of Mental Disorders, 4th ed., 1994). The diagnosis was performed according to a 
three-step procedure. The examining physician made a preliminary diagnosis, which was 
followed by an independent diagnosis based on computerized data. If these diagnoses were 
incongruent, a supervising physician made a third and final diagnosis. Cognitive measures 
that aided diagnosis included the Mini Mental State Examination (MMSE; Folstein, Folstein, 
& McHugh, 1975), the Clock test (Manos & Wu, 1994), and questions regarding memory, 
orientation, executive functioning, interpretation of proverbs, and problem solving. AD was 
diagnosed according to NINCDS-ADRDA criteria (McKhann et al., 1984). In Study III, we 
conducted analyses including all incident dementia cases as well as analyses restricted to the 
incident AD cases. For all other studies in the thesis, those participants who received a 
dementia diagnosis at baseline were excluded.  
3.4 MRI ACQUISITION AND VOLUMETRIC MEASUREMENT  
MRI data were acquired on a 1.5 T MRI scanner (Philips Intera, The Netherlands). 3D fast 
field echo (FFE) T1, axial spin echo (SE) Proton Density/T2, axial fluid-attenuated inversion 
recovery (FLAIR), and axial diffusion tensor imaging (DTI) were acquired. In this thesis, the 
axial 3D FFE T1 images repetition time (TR) = 15 ms, echo time (TE) = 7 ms, Flip angle = 
15◦, number of axial slices = 128 with thickness = 1.5 mm and in plane resolution 0.94 × 
0.94mm2, no gap, Field of view (FOV) = 240, matrix = 256 × 256) were used.   
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Manually traced measures of the HC were conducted in HERMES workstation (Nuclear 
Diagnostics Stockholm, Sweden) and used as an outcome measure in Study I. The delineation 
of the HC included the HC proper (Ammon´s horn), the dentate gyrus, the subiculum and 
some white matter (alveus, fimbria; Qiu et al., 2012). HC volumes for both hemispheres 
were combined and we corrected for head size by adding intracranial volume (ICV) as a 
covariate.  
In Study IV, T1-weighted images were used to quantify gray-matter volumes according to 
the unified-segmentation approach (Ashburner, 2007) in SPM12b (Statistical Parametric 
Mapping, Welcome Trust Centre for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm/) 
implemented in Matlab 10 (The Mathworks, Inc). Following preprocessing, 8 regions of 
interest per hemisphere were defined: lateral prefrontal cortex (LPFC), orbitofrontal cortex 
(OFC), inferior parietal lobule (IPL), inferior temporal cortex (ITC), primary visual cortex 
(VC), HC, caudate (CD), and putamen (PT). Masks were created based on corresponding 
Broadmann areas for each region, using the MRIcron atlas for LPFC (Brodmann areas 8, 9, 
10, 45, and 46), OFC (Brodmann areas 11 and 47), IPL (Brodmann area 40), and ITC 
(Brodmann area 20). The WFU Pickatlas AAL was used for the remaining masks. As such, 
16 masks were created to extract mean regional volumes for each participant. To increase 
anatomic validity, the fit of each mask was visually inspected and optimized in terms of 
clear separation. Volumetric data were corrected for ICV, according to the analysis of 
covariance method (Raz et al., 2005).  
3.5 GENOTYPING  
DNA was extracted from peripheral blood samples and genotyping was performed using 
MALDI-TOF analysis on the Sequenom MassARRAY platform at the Mutation Analysis 
Facility, Karolinska Institutet. The following polymorphisms were analyzed in this thesis: 
TOMM40 rs11556505 and rs2075650, PICALM rs3851179 and rs541458, CLU 
rs11136000, BIN1 rs744373, and APOE rs7412, rs429358. In Studies II and III, we utilized 
a combined GRS of the following alleles: PICALM (rs3851179 G allele, rs541458 T allele), 
BIN1 (rs744373 G allele), and CLU (rs11136000 T allele). The aggregate GRS was based 
on the presence of 0, 1 or 2 risk alleles for each polymorphism. Following a median split, 
groups were divided into low GRS (0-4) and high GRS (5-8) and analyzed accordingly.  
3.6 PHYSICAL ACTIVITY  
Physical activity was assessed using a self-administered questionnaire (Rydwik et al., 
2013). Participants reported if they had been physically active within the past 12 months in 
terms of levels of intensity (light such as walks or short bike rides, moderate or intense such 
as brisk walks or jogging) and frequency (<2–3 times/month, 2–3 times/month, several 
times/week, and every day). Three categories were created to quantify physical activity: (a) 
inadequate (2–3 times per month in light and/or moderate/intense exercise); (b) health- 
enhancing (light exercise several times per week or every day); or (c) fitness-enhancing 
(moderate/intense exercise several times per week or every day), based on recommendations 
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from the World Health Organization and the American College of Sports Medicine (Nelson 
et al., 2007; WHO, 2010). 
3.7 INFLAMMATORY MARKERS  
Blood serum markers of inflammation were extracted from peripheral blood samples (fasting 
was not compulsory; Papenberg, Ferencz, et al., 2016). IL-1β, IL-6, IL-10, IL-12p40, IL-
12p70, G-CSF, and TNF-α were analyzed with a multiplex suspension array system using the 
Bioplex Luminex 200 instrument (Bio-Rad Laboratories, Hercules, CA) and the 
MILLIPLEX® MAP Human Cytokine/Chemokine panel (Merck Millipore, Darmstadt, 
Germany). To control for potential confounding by acute inflammation, CRP was measured 
using standard procedures (Buckley, Fu, Freeman, Rogers, & Helfand, 2009). 
3.8 ADDITIONAL VARIABLES   
Independence in terms of ADLs (e.g., dressing, hygiene) and IADLs (e.g., shopping, 
cooking) was assessed by nurses and analyzed in terms of number of dependencies. The 
occurrence of chronic diseases was determined by physicians and based on medical history, 
laboratory data, and current medication use. Disease diagnoses were based on the ICD-10 
classification and included, but were not limited to, circulatory diseases, musculoskeletal 
diseases, and endocrine diseases. Number of chronic diseases was used as a covariate in 
Study II, where we also adjusted for vascular risk factors such as smoking, high cholesterol, 
and Body Mass Index (BMI). In Study IV, cardiovascular burden was assessed in terms of 
aggregates of cardiovascular risk factors (stage-2 hypertension, high cholesterol ≥6.5 
mmol/L, obesity ≥30 kg/m2, diabetes, smoking) and cardiovascular diseases (ischemic heart 
disease, atrial fibrillation, heart failure; Welmer, Angleman, Rydwik, Fratiglioni, & Qiu, 
2013). Finally, the MMSE (Folstein et al., 1975) was used for assessment of global cognitive 
functioning. 
3.9 STATISTICAL ANALYSES  
Study I and II used ANOVA and χ2 tests (IBM SPSS 19) to assess group differences in 
background variables. ANCOVAs were used to investigate main and interaction effects of the 
independent variables. Several factors were included as covariates including age, sex, 
education, and ICV in Study I. In Study II, factors associated with cognitive functioning such 
as smoking, high cholesterol, BMI, ADL, number of chronic diseases, and APOE gene status 
were controlled for. In Study III logistic regressions were performed in SAS to estimate the 
OR and 95% confidence interval for incident dementia. Here, models were adjusted for age, 
sex, education, APOE, and ADL. Analyses in Study IV were conducted within a structural-
equation modeling (SEM) framework using AMOS 7.0 (Arbuckle, 2006) to estimate a model 
specifying latent gray-matter factors. Inflammatory markers and physical activity were added 
as predictors in the model and age, sex, education, IADL, cardiovascular risk factors, and 
CRP levels were added as regressors.  
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3.10 ETHICAL CONSIDERATIONS 
The SNAC-K project complies with the declaration of Helsinki. The ethical committee at 
Karolinska Institutet approved baseline data collection, and the regional ethical review board 
approved data collection for follow-up assessments. All participants gave informed consent, 
and had the option to drop out of the study at any time. If the participant was cognitively 
impaired (MMSE ≤22), informed consent was obtained from next-of-kin.  
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4 RESULTS  
4.1 STUDY I  
Mitochondrial dysfunction has been suggested as a potential pathogenic mechanism in brain 
aging. Yet, little is known about the influence of TOMM40 SNPs on episodic memory and 
volume of the HC in healthy aging. In Study I, we assessed the influence of TOMM40 
polymorphisms (rs11556505 and rs2075650) on episodic memory performance and 
hippocampal volume in healthy older adults.  
Participants: 424 dementia-free individuals (Rangeage = 60-87, Mage = 69.91, SDage = 8.63) 
from the SNAC-K baseline MRI assessment were included in Study I. Participants were 
screened for neurological disorders, MMSE ≤ 24, and depression.  
Results: There were no main or interaction effects of TOMM40 polymorphisms on episodic 
free recall or volume of the HC. Yet, a series of partial correlations showed that there was a 
significant link between HC volume and episodic memory performance only in those 
carrying an APOE ε4 allele. Stratifying APOE across TOMM40 polymorphisms showed that 
the association remained significant only in those having the combination of disadvantageous 
APOE ε4, TOMM40 rs2075650 G, and rs11556505 T alleles.  
Conclusions: TOMM40 polymorphisms did not influence episodic memory performance or 
HC volume in healthy older adults. However, there was an association between episodic 
memory performance and HC in those carrying disadvantageous alleles of both APOE and 
TOMM40. This pattern suggests that APOE ε4 carriers with additional TOMM40 risk alleles 
may rely more strongly on HC volume for episodic memory performance. These findings 
suggest that TOMM40 should be considered in cognitive aging research, in addition to APOE. 
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4.2 STUDY II  
PICALM, BIN1 and CLU are top candidate genes for AD and certain SNPs have been 
associated with reduced episodic memory performance in healthy aging. The susceptibility 
model holds that individuals with disadvantageous alleles may not only be more vulnerable to 
certain conditions, but also more prone to benefit from environmental influences, such as 
being physically active in old age. Here we investigate the effects of a GRS based on 
PICALM (rs3851179, rs541458), BIN1 (rs744373), and CLU (rs11136000) polymorphisms, 
examining whether a high GRS is associated with episodic memory performance in healthy 
aging and if there are interactions with physical activity.  
Participants: 2480 dementia-free individuals (Rangeage = 60-100, Mage = 72.63, SDage = 10.10) 
from the SNAC-K baseline neuropsychological assessment were included in Study II. 
Participants with neurological disorders, MMSE ≤ 24, and preliminary dementia diagnosis at 
first follow-up were excluded.  
Results: There was a main effect of GRS on both free recall and recognition, such that those 
who had a high GRS performed worse than those who had a low GRS. A similar pattern was 
evident for physical activity, where individuals who were active outperformed those who 
were inactive in free recall, but not in overall recognition. Interestingly, there was an 
interaction between physical activity and GRS, such that the combination of being physically 
inactive together with having a high GRS was most detrimental to episodic memory 
performance. Moreover, those who were inactive with a high GRS were also more likely to 
report a less clear recollection of an item and tended to rely more on familiarity in episodic 
recognition. Importantly, the effects of GRS on episodic memory were eliminated among 
those who were physically active. Of note is also that this interactive pattern was only 
observed for episodic memory. For the tasks assessing semantic memory, verbal fluency, and 
speed, there were no genetic effects, and there were main effects of physical activity for all 
measures, except semantic memory. 
Conclusions: In line with the susceptibility model, our findings confirmed that individuals 
with the most disadvantageous alleles benefit the most from environmental influences. 
Having a high GRS of PICALM, BIN1, and CLU polymorphisms was associated with 
reduced episodic memory performance in healthy aging. This effect was attenuated by 
maintaining a physically active lifestyle. 
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4.3 STUDY III 
In Study II, we demonstrated that a high GRS of PICALM, BIN1 and CLU SNPs is associated 
with impaired episodic memory performance. In Study III we tested whether the same GRS, 
and physical activity predicts incident dementia.  
Participants: Individuals (Rangeage = 60-100, Mage baseline = 70.54, SDage baseline = 9.49) from the 
SNAC-K baseline assessment who were followed for a 6-year time period were included in 
Study III. After screening for dementia and other neurological disorders at baseline, the 
effective sample included 1891 persons. During the 6-year follow-up period, 200 individuals 
developed dementia (125 received an AD diagnosis) and 1691 remained alive and non-
demented. 
Results: In line with previous work, physical inactivity was associated with an increased risk 
of dementia and AD. However, a high GRS of PICALM, BIN1 and CLU polymorphisms was 
not associated with increased dementia risk. Having the combination of a high GRS and 
being physically inactive was strongly related to incident dementia (OR=2.70, CI=1.56-4.67) 
and AD (OR=3.58, CI=1.90-6.75). However, there was no significant interaction effect 
between genetic risk and physical activity with regard to future dementia. 
Conclusions: This study shows that physical inactivity is associated with incident dementia. 
Although the interaction between physical inactivity and genetic risk did not reach statistical 
significance, future studies may continue to investigate whether an active lifestyle can 
counteract the negative effects of genetic susceptibility. Preferably, such research should 
include larger sample sizes and consider additional candidate genes for dementia.  
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4.4 STUDY IV 
Inflammatory factors have been suggested to influence the brain negatively in aging. On the 
other hand, the brain-maintenance view holds that an active lifestyle in old age could preserve 
brain integrity and thereby cognition. Here, we investigate the influence of inflammatory 
biomarkers and physical activity on gray-matter volume and global cognitive decline.  
Participants: 414 dementia-free individuals (Rangeage = 60–87 years, Mage = 71.8 years; 
SDage = 9.0 years) from the SNAC-K baseline MRI assessment were included in Study IV. 
Participants that were included were free of other disorders, including stroke, epilepsy, and 
brain tumors.  
Results: Participants who were physically inactive had consistently smaller gray-matter 
volumes. This was true also when controlling for confounders, such as age, sex, education, 
IADL, as well as cardiovascular risk and disease. Although none of the inflammatory 
biomarkers were associated with gray-matter volumes, there was an interaction between 
physical activity and two of the inflammatory markers. Specifically, a high level of IL-12p40 
was associated with smaller gray-matter volumes of LPFC and HC, but only in individuals 
who were physically inactive. High G-CSF, a factor that downregulates inflammation, was 
associated with larger gray-matter volume of the LPFC and HC in the same group, only when 
all other inflammatory factors were included in the model. Interestingly, global cognitive 
decline across a 6-year time period was most evident in those participants who were 
physically inactive, had high IL-12p40 levels, and showed smaller LPFC and HC volumes. 
Conclusions: The observed pattern of data indicates that inflammatory cytokines are most 
detrimental in combination with physical inactivity in terms of having negative effects on 
brain volume and cognition.  
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5 DISCUSSION  
5.1 SUMMARY OF FINDINGS  
The aim of this doctoral thesis was to investigate the role of genetic and inflammatory 
biomarkers on cognition, brain aging and dementia. Fundamentally, the goal was to 
contribute to the understanding of gene-environment interactions in an effort to elucidate the 
complex phenotypes of cognitive aging and AD. The following are some of the main 
findings: In Study I, there was some support for the added influence of TOMM40 
polymorphisms, over and above APOE, on the link between HC volume and episodic 
memory performance. Although these findings indicate that TOMM40 should be considered 
in addition to APOE, more research is needed to confirm an independent association. In 
Study II we observed direct effects of genes on cognition, where a GRS, based on PICALM, 
BIN1 and CLU alleles, was associated with episodic memory performance in healthy older 
adults. In Study III, the same risk score was not associated with AD, and although the 
combination of a high GRS and physical inactivity was most strongly related to dementia and 
AD, the interaction did not reach significance. In Study II, we found a significant interaction 
between physical activity and GRS for episodic memory, suggesting that an active lifestyle 
may especially benefit those who are most susceptible to AD.  
The benefits of physical activity in older adults were further demonstrated in Study IV. Here, 
the effects of inflammation on HC and LPFC volume were observed only in persons who 
were inactive. This indicates that systemic inflammation may influence brain and cognitive 
decline in those individuals who are inactive. In summary, this thesis demonstrates the 
benefits of physical activity in old age as it interacts with genetic and inflammatory 
biomarkers in aging. Moreover, we demonstrated the benefit of considering the combined 
effects of genes on cognition, brain integrity, and dementia, whether in GRS constellations or 
stratified across APOE status. Our findings are consistent with the hypothesis that 
mechanisms such as mitochondrial dysfunction and inflammation may play a role in 
cognitive aging and AD, which are complex phenotypes influenced by many factors.  
5.2 TOMM40, MEMORY, AND THE HIPPOCAMPUS  
In Study I, our main analyses were not able to demonstrate an independent effect of APOE, or 
TOMM40 on HC volume and episodic memory performance in older adults. This may have 
been due to the relatively small and healthy sample especially in the SNAC-K MRI 
subsample, and that the effect of preclinical dementia was stringently controlled for. The lack 
of influence of APOE is surprising, as the literature supports an influence of APOE, 
especially on gray-matter integrity in aging (for a review, see Ferencz et al., 2012). However, 
volumetric changes are evident also in old adults with low genetic risk, suggesting that 
atrophy alone may not be sufficient in distinguishing individuals who will subsequently 
develop AD (Fjell, McEvoy, Holland, Dale, & Walhovd, 2013). This may explain why there 
was no direct influence of APOE and TOMM40 on HC volume in Study I. Furthermore, one 
study suggests that the effects of TOMM40 may be age-dependent, and occur only before the 
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age of 60 (Caselli et al., 2012), which is prior to the entry point for individuals in the current 
study.  
Despite the lack of direct effects, there was a positive association between HC volume and 
episodic memory in APOE ε4 carriers with additional TOMM40 (rs20756505, rs1155650) 
risk alleles. This suggests that those who are genetically susceptible to AD are more likely to 
depend on HC volume for episodic memory accuracy. Although there were no TOMM40-
related structural changes of the HC, our findings are in support of the view that there may be 
TOMM40-related functional changes within the mitochondria of the HC at this stage. This 
might explain why we observed a combined genetic influence of APOE and TOMM40 on the 
HC-episodic memory link. Future studies utilizing markers of glucose metabolism and 
oxidative stress may confirm a role of mitochondrial dysfunction on HC integrity.  
Examining the independent or combined effects of APOE and TOMM40 more accurately 
describe the association from this region, as ascribing the effect to APOE and not considering 
the effects of TOMM40 may result in overlooking an important association (Roses et al., 
2016). 
Conclusion: Although there was no direct effect of TOMM40 on HC volume or episodic 
memory in healthy aging, we did find an association between volume and performance in 
APOE ε4/TOMM40 risk allele (rs2075650 G and rs11556505 T) carriers. This could be an 
early indicator of mitochondrial dysfunction within the HC. Furthermore, it highlights the 
necessity of considering these genes in combination. 
5.3 PICALM, BIN1, CLU, AND MEMORY  
Study II is the first to demonstrate that a combined GRS of PICALM, BIN1, and CLU risk 
alleles is associated with worse episodic memory performance in old age, independent of 
APOE. Whereas multilocus genotype patterns of these genes have previously been associated 
with episodic memory (Barral et al., 2012), we demonstrate that the effect is independent of 
APOE and that a GRS of these genes interacts with physical activity in old age. The 
association between high genetic risk and episodic memory appears to be robust, as we were 
recently able to replicate the association in an independent sample (Papenberg, Becker, et al., 
2016). 
In line with our hypothesis, physical activity interacted with genetic risk on episodic memory, 
such that those who had a high GRS and were physically active outperformed individuals 
with a high GRS and inadequate physical activity. When recognition was further probed, the 
high GRS/inactive participants had less conscious recollection of the items and relied more 
heavily on familiarity. Recollection and familiarity are distinct memory processes with 
recollection depending primarily on the integrity of the HC (Yonelinas, 2001). This pattern 
suggests that a high GRS may be detrimental to HC volume and that physical activity may 
help preserve it. Indeed, BIN1 is primarily expressed within the hippocampus (Holler et al., 
2014), and SNPs of PICALM and BIN1, that were included in this GRS have been associated 
with HC and entorhinal cortex volumes (Biffi et al., 2010). Taken together, these findings 
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suggest that PICALM, BIN1 and CLU genes may modulate MTL vulnerability in old age. The 
effects of high GRS were specific to episodic memory, as perceptual speed, vocabulary, 
general knowledge, and verbal fluency were not influenced by the GRS. There is always the 
caveat that common genetic variations account only for a small portion of the explained 
variance (<1%) in performance. This holds true also for the associations between high GRS 
and episodic memory in Study II of this thesis. Although the effect sizes on episodic 
memory are small, their clinical significance may still be of relevance. 
Conclusion: Study II confirmed our hypothesis that a high GRS of PICALM, BIN1 and CLU 
risk alleles negatively influences episodic memory performance in old age. The pattern of 
episodic memory deficits in those with high GRS/physical inactivity suggest that these 
polymorphisms may be linked to hippocampal integrity in old age. Interestingly, physical 
activity interacted with GRS and influenced episodic memory performance.     
5.4 PLASTICITY GENES 
In line with the brain-maintenance view, the results of Study II suggest that individuals who 
are more susceptible to AD may benefit the most from environmental influences, such as 
physical activity. This supports the notion that genes associated with an increased risk of AD 
may not only be vulnerability genes that increase the risk of a disease, but they may also be 
considered plasticity genes that are more receptive to environmental influence (Belsky et al., 
2009). This assertion is not new. Darwin (1809), stated that it is not the strongest who 
survive, but those who are more responsive to change. It is not customary to consider 
vulnerability genes as plastic, yet, the differential susceptibility hypothesis suggests that 
some genes may be just that (Belsky et al., 2009). Rather than simply conferring risk or 
vulnerability to diseases, participants who harbor unfavorable genetic combinations may be 
more readily influenced by positive environmental factors such as remaining physically 
active (Belsky et al., 2009). This has been shown for the BDNF gene, where physical 
activity counteracted the negative effects of the Met allele on working memory 
performance (Erickson et al., 2013). We have been able to demonstrate similar findings 
with regard to PICALM, BIN1, and CLU genes, in terms of episodic memory performance. 
However, as physical activity was not measured objectively, and only cross-sectional 
associations were examined, we have to be cautious in assuming a direct causal link.  
In Study II, we demonstrated an effect of high GRS on episodic memory performance 
indicating that hippocampal integrity may be compromised in individuals with high genetic 
risk. A possible explanation for the observed gene-lifestyle interaction is that physical 
activity may attenuate this association by preserving the integrity of brain areas important 
to memory, such as the HC and PFC (Rovio et al., 2010). The literature has consistently 
shown that physical activity and aerobic exercise not only protects against volume loss, but 
may also reverse age-related HC shrinkage (Erickson et al., 2009, 2014; Kramer & 
Erickson, 2007). Furthermore, physical activity appears to utilize the brain´s natural 
capacity for plasticity (Kramer & Erickson, 2007). Our findings in Study II is consistent 
with the view that the protective effect of physical activity may be especially pronounced 
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for individuals with high genetic risk. This does not imply that those who have a genetic 
advantage do not benefit from a physically active lifestyle; however, it suggests that those 
with high genetic risk may benefit more. 
Conclusion: We were able to demonstrate that physical activity, already at a moderate 
level, is associated with health benefits in terms of counteracting the negative effects of 
being at high genetic risk of AD on episodic memory. This may be a result of beneficial 
influence of physical activity in the hippocampal area. 
5.5 PICALM, BIN1, CLU, AND ALZHEIMER’S DISEASE  
In Study III, there was no effect of a high GRS of PICALM, BIN1 and CLU risk alleles on 
dementia incidence. Physical inactivity, however, was associated with increased risk of 
developing AD during a 6-year follow-up period. Although stratified analyses indicated that 
the combination of having a high GRS and physical inactivity was strongly associated with 
incident dementia, the interaction effect was not reliable.  
As the majority of associations of PICALM, BIN1, and CLU alleles with AD come from large 
GWAS, it is possible that the lack of genetic association in our study reflects low statistical 
power. Toward this end, note that the same GRS was positively associated with memory in 
the better-powered Study II. Moreover, heritability estimates based on SNPs are generally 
considerably lower than those based on twin studies, which reflects complex gene-gene and 
gene-environment interactions (Reynolds & Finkel, 2015). Furthermore, it is likely that many 
common genes with small effects act on the polygenic nature of AD. Although polygenic risk 
scores can double  the prediction of AD (Escott-Price et al., 2015; Harrison et al., 2016), the 
current GRS constellation showed no effects on AD. It is likely that epistatic effects are at 
play in the disease (Hohman, et al., 2013), meaning that the effect of one gene is dependent 
upon another in terms of modification. Although the SNPs in the current GRS were chosen 
based on their associations with AD and relevant biological mechanisms, important genes 
may be missing from the equation. This signifies the importance of future studies considering 
multiple gene interactions and overlapping biological mechanisms in creating future risk 
scores. 
Conclusion: The results did not support our hypothesis as a high GRS of PICALM, BIN1 and 
CLU was not associated with incident dementia in our population. Moreover, there was no 
reliable interaction between high GRS and physical inactivity.  
5.6 INFLAMMATORY CYTOKINES 
Study IV supports the brain-maintenance view and is in line with the other studies of this 
thesis showing the benefits of an active lifestyle in old age. In accordance with previous 
research (Voelcker-Rehage & Windisch, 2013), Study IV shows that physical inactivity is 
associated with smaller gray-matter volume across several regions including the HC, LPFC, 
OFC, and the CD. Inflammatory biomarkers were not associated with gray-matter integrity; 
however, there was an interaction between physical activity and the inflammatory biomarker 
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IL-12p40. Negative effects of IL-12p40 on hippocampal and LPFC volumes were observed 
only in participants who were inactive. In the same inactive group, high levels of G-CSF were 
associated with larger volumes in these regions. This may seem counterintuitive; however, G-
CSF has been suggested to downregulate inflammation (Sanchez-Ramos et al., 2009). As 
such, the association with gray-matter volume in the physically inactive groups may actually 
reflect a state of inflammation. Notably, the effect of G-CSF was only present when all other 
markers were included in the model, indicative of a suppression effect. Furthermore, the 
combination of physical inactivity/high levels of IL-12p40 was associated with global 
cognitive decline during the 6-year follow-up. In line with the observations in Study II, the 
HC and the PFC may be especially sensitive to the effects of physical activity, as markers of 
inflammation only had a negative influence on gray-matter volume in those who were 
physically inactive. Interestingly, none of the other cytokines (IL-6, IL-10, IL-1β, TNF-α) 
that have previously been linked to brain and cognition (Marsland et al., 2008; H. Zhang et 
al., 2016) were associated with brain volume in the current study.  
We know that the immune system becomes compromised in aging (López-Otín et al., 2013) 
and our findings indicate that systemic inflammation may be especially prominent and 
associated with brain integrity in people who are inactive. The pattern of increased IL-12p40 
suggests that there is a state of inflammation that influences HC and PFC volumes, but only 
in those who are physically inactive. Although there was no overall association between 
physical activity and inflammatory markers in our study, others have shown that physical 
activity modulates inflammation by lowering inflammatory markers (Hamer et al., 2012). 
Mechanisms through which physical activity and exercise may prevent cognitive decline and 
protect against brain aging include promoting angiogenesis (Lista & Sorrentino, 2010), 
neurogenesis (Kempermann, 2008), and by reducing oxidative stress (Marosi et al., 2012). As 
such, it is likely that the benefits of physical activity may act through several different 
pathways, which might explain why there was no direct association between physical activity 
and inflammatory levels in this study.  
Conclusion: Our findings extend previous research on the benefits of staying physically 
active in old age. They suggest that the negative effects of inflammatory cytokines on gray-
matter volume and cognitive decline are only present in individuals who are inactive. The 
observed pattern indicates that IL-12p40 could be an early marker of subsequent cognitive 
decline in combination with physical inactivity.      
5.7 ETIOLOGY OF ALZHEIMER’S DISEASE   
Taken together, our findings might reflect that there are several pathogenic mechanisms that 
influence cognitive heterogeneity and dementia in old age. Further research will have to 
disentangle which specific pathways the genetic and inflammatory biomarkers assessed in 
this thesis influence. Our findings are compatible with the view that a number of non-amyloid 
processes may influence memory, brain volume, and AD. This does not mean that amyloid is 
not involved in the pathological process; it rather implies that other pathological processes are 
also important. For instance, in Study I, the influence of TOMM40 on HC volume and 
 32 
episodic memory, albeit limited, implicates mitochondrial involvement in aging. In Study II 
and III, the influence of a high GRS on memory and AD, especially in combination with 
physical inactivity, suggests several amyloid-dependent pathways. The high GRS SNPs 
examined influence lipid metabolism, immune system response, iron homeostasis, 
neurofibrillary tangle formation, synaptic vesicle endocytosis, glucose metabolism, and 
apoptotic processes (Jones et al., 2010; Maglott et al., 2005; Xu et al., 2014; Zlokovic et al., 
1996). That said, the genes in this thesis are also involved in amyloid-dependent processes 
(Xu et al., 2014). Finally, in Study IV, the combined effect of inflammatory cytokines and 
physical inactivity signifies the importance of considering inflammatory mechanisms as an 
early and pathogenic hallmark of brain and cognitive aging. Furthermore, the interaction with 
physical activity implicates yet another set of biological mechanisms that may serve to 
protect the brain in aging, such as neurogenesis, angiogenesis, and reduction of oxidative 
stress. The extent to which the genes investigated in this thesis exert their negative effects in 
these pathways remains unclear. However, for inflammatory markers it is likely that we 
actually approximate the role that inflammation plays in aging. 
Conclusion: Taken together, these findings support the view that several biological 
mechanisms are important in cognitive and brain aging.  
5.8 THE BENEFITS OF PHYSICAL ACTIVITY   
Although this thesis was primarily focused on the mitigating role of physical activity and its 
potential interaction with genetic and inflammatory markers, it should be noted that one of 
the most consistent finding of the thesis was the benefits of physical activity in old age. This 
is in line with a vast amount of studies on the benefits of physical activity on cognitive aging 
(Prakash, Voss, Erickson, & Kramer, 2015) and AD (Kramer & Erickson, 2007).  
In Study II, the benefits of physical activity were evident in terms of episodic memory 
performance. These findings suggest that participating in health- or fitness-enhancing 
activities several times per week is associated with better episodic memory performance in 
old age. These findings support previous research suggesting that physical activity preserves 
memory in aging (Lista & Sorrentino, 2010). Participating in low-intensity activities such as 
usual paced walks and short bike rides may be sufficient in terms of benefits for episodic 
memory as we age. Study III further corroborates the benefits of physical activity by 
demonstrating that individuals who are physically inactive are more likely to develop 
dementia and AD which is in line with previous reports (Rovio et al., 2005; Tolppanen et al., 
2015). Thus, physical activity may continue to serve as an important primary prevention 
strategy (Winblad et al., 2016).  
The findings in Study IV also indicate that it is physical inactivity and a sedentary lifestyle 
that should be avoided, as the negative effects of inflammation were only seen in those who 
were inactive. Although no direct influence of physical activity on inflammatory cytokines 
was observed, these findings suggest that the effects of inflammation may be especially 
detrimental in individuals who are inactive. Interestingly, in Study IV we were able to 
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replicate previous work on the benefits of staying active by showing an association between 
physical activity and regional gray-matter volumes (Rovio et al., 2010; Voelcker-rehage & 
Windisch, 2013). Individuals who were inactive showed consistently smaller gray-matter 
volumes across the brain. 
Conclusion: The studies of the current thesis support the benefits of physical activity in older 
adults. We demonstrate that physical activity already at low levels of intensity is beneficial in 
terms of memory and brain aging. Moreover, a sedentary lifestyle is associated with an 
increased risk of developing dementia and AD. These findings support the view that we 
should continue to promote physical activity in line with WHO recommendations, to reduce 
the risk of dementia, and maintain memory functioning and brain health in aging. 
5.9 IMPLICATIONS FOR PREVENTION STRATEGIES  
Our findings are consistent with the hypothesis that several factors influence the 
heterogeneity of memory performance, brain aging, and dementia risk, which makes it 
imperative to consider multiple factors when designing future intervention studies. 
Randomized controlled trials with multi-domain lifestyle interventions are already well on 
their way (Ngandu et al., 2015). Our findings further highlight the importance of considering 
other genetic influences, besides APOE, in future clinical trials and interventions. The vast 
number of clinical trials that have failed may target individuals too late in the disease process. 
With that in mind, genetic and inflammatory biomarkers could identify at-risk individuals 
early in the disease process. Our findings also suggest that some may benefit more from 
remaining active in old age. Randomized controlled trials will be needed to determine if the 
benefits of physical activity in this thesis can be replicated. This work would benefit from 
adding biomarkers of, for instance, oxidative stress that were not measured in this thesis. To 
combat the dementia epidemic, we need to target such modifiable risk factors early. Although 
genes are not traditionally considered modifiable risk factors, our data suggest that they may 
be plastic. Recent estimations indicate that utilizing genetic risk scores could lower the costs 
of clinical trials, by enriching the trials with individuals most likely to develop dementia (Hu 
et al., 2013).  
Conclusion: Our findings highlight the benefit of considering genetic and inflammatory 
biomarkers in future clinical trials for AD, in combination with environmental influences to 
target at-risk individuals early in the disease progression. 
5.10 LIMITATIONS  
A main limitation of this work is the cross-sectional nature of some of the empirical studies. 
For instance, we would benefit from knowing if the genes examined in this thesis are 
associated with brain and cognitive changes. Moreover, it is likely that measures of physical 
activity and inflammation change over time, and it would have been preferable to also assess 
these measures longitudinally to examine if there is a direct influence of physical activity on 
inflammation.  
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Another limitation concerns the lack of objective assessment of physical activity. It has been 
shown that subjective and objective measures of physical activity can differ (Dyrstad, 
Hansen, Holme, & Anderssen, 2014), which may be especially critical in participants with 
poor memory performance. The observational nature of the studies in this thesis warrants for 
caution when interpreting the causality of physical activity associations. Intervention studies 
will have to confirm potential gene-environment interactions in this regard. Furthermore, 
there is also the possibility that lack of physical activity is a result of other functional 
problems, limiting participation. However, the associations in this thesis remained after we 
controlled for various confounders such as ADL, and chronic diseases.   
In terms of structural imaging of the brain, it is clearly desirable to use more advanced MRI 
protocols with higher resolution than what was available in SNAC-K. However, the 
longitudinal nature of the SNAC-K project limits our ability to update scanner protocols.  
Concerning generalizability of the current data, note that the findings are based on an urban-
dwelling, highly educated Swedish population. In terms of dementia, it is possible that the 
results of Study III were influenced by survival bias as physical inactivity is associated with 
mortality (Groot et al., 2004). However, as pointed out by others, if participants who had 
deceased were more likely to have high genetic risk and be physically inactive, it is more 
likely that we underestimated the effects of genes and physical activity on dementia in our 
sample (Kivipelto et al., 2008). Future studies should consider also the diagnostic, genetic, 
and lifestyle status of those who have deceased. 
5.11 FUTURE DIRECTIONS 
We have been able to demonstrate that there are several genetic, inflammatory, and 
environmental markers that influence cognitive heterogeneity, brain integrity, and risk of 
dementia. Our results support the notion that normal and pathological aging is a multifactorial 
process involving mitochondrial, inflammatory, and most likely amyloid processes. Besides 
systemic inflammation, none of these other pathogenic markers were measured in this thesis. 
Thus, it is not possible to ascertain the biological underpinnings of the genetic effects in this 
thesis. Future studies would benefit from assessing, for example, markers of oxidative stress 
in unison with genetic variation.  
In terms of genetic associations, future studies will continue to benefit from considering 
multiple genes in unison and polygenic AD scores in order to understand the polygenic 
structure of cognitive aging and dementia (Escott-Price et al., 2015; Harrison et al., 2016). 
Such analyses allow us to assess the SNPs that may contribute to the polygenic makeup of 
cognitive aging and AD, but that fail to meet the accepted p-value threshold for GWAS. It 
was recently shown that, even after excluding SNPs that are in LD, as many as 24 genomic 
regions were associated with AD (Escott-Price et al., 2015). Moreover, there is increasing 
support for the notion that episodic memory is a polygenic behavioral trait (Papassotiropoulos 
& de Quervain, 2011). As such, rather than focusing on single SNPs or even genetic-risk 
scores, creating individual genetic risk profiles will be more accurate in terms of predicting 
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disease. The likelihood that episodic memory and AD are complex phenotypes influenced by 
many different genes is reflected also in the small effects of the SNPs in this thesis. Although 
memory and AD are highly heritable, the contribution of each SNP is relatively small. A 
recent GWAS with quantitative traits identified several new loci associated with HC volume 
and shape that predicted AD (Hibar et al., 2017). These findings support the notion that 
common variants with small effect sizes contribute to complex phenotypes such as AD. 
Others suggest we should move the focus from common variants with small effect sizes and 
try to identify rare variants with high penetrance in next generation sequencing (Ridge et 
al., 2013).   
Traditionally, genes are not considered as biomarkers, yet they may be stable predictors of 
AD. Ultimately, genetic risk algorithms could be further developed to include genetic, 
lifestyle and inflammatory biomarkers to identify individuals at high risk. Efforts to 
develop such biomarkers have commenced, focusing on TOMM40 and APOE (Lutz, 
Sundseth, et al., 2016). We maintain that to benefit from such strategies, we must shift the 
focus from single-locus genetic approaches to examine the combined effects of genes in 
unison. For research purposes, these measures would preferably be combined with 
objective measures of physical activity. To further enhance our understanding of genetic 
influences in cognitive aging it will be necessary to assess potential pleiotropic effects of 
SNPs from a life-course perspective. According to the resource-modulation hypothesis the 
effects of genetic variation is limited in younger adults, but magnified in old age (Papenberg 
et al., 2015). Such effects have already been demonstrated for APOE ε4 carriers (for a review 
see Papenberg et al., 2015). It remains to be seen if there are any pleiotropic effects of the 
SNPs studied in this thesis.  
One potential mechanisms by which genes are plastic is through epigenetic mechanisms. To 
understand how physical activity may influence the effects of genes, epigenetic research will 
become increasingly important. Some such studies are already well on the way, and focus on 
how physical activity may be involved in gene expression by changing DNA methylation 
(Horsburgh, Robson-Ansley, Adams, & Smith, 2015). While still in their early stages, such 
studies will become increasingly important especially for understanding how physical activity 
can mitigate the influence of inflammation. Moreover, it may be important to consider 
personality factors as a potential influence as recent research shows that genes may interact 
with some personality traits (Saptoka, Wiebe, Small, & Dixon, 2016).  
Although we have demonstrated that physical activity is beneficial in terms of brain-
maintenance in aging, and that genes may be plastic, future longitudinal studies as well as 
intervention studies are necessary to confirm such associations.  
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